Advisors Asset Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.57M Buy
12,119
+3,337
+38% +$1.88M 0.1% 275
2026
Q1
$5.21M Buy
8,782
+1,758
+25% +$876K 0.09% 316
2025
Q4
$3.42M Buy
7,024
+2,288
+48% +$1.07M 0.06% 428
2025
Q3
$1.99M Buy
4,736
+723
+18% +$243K 0.03% 600
2025
Q2
$1.15M Buy
4,013
+121
+3% +$36.2K 0.02% 730
2025
Q1
$1.2M Buy
3,892
+1,129
+41% +$387K 0.02% 704
2024
Q4
$975K Sell
2,763
-2,024
-42% -$744K 0.02% 745
2024
Q3
$1.72M Sell
4,787
-196
-4% -$66.2K 0.03% 604
2024
Q2
$1.59M Sell
4,983
-149
-3% -$39.4K 0.03% 601
2024
Q1
$1.18M Sell
5,132
-1,819
-26% -$410K 0.02% 700
2023
Q4
$1.53M Sell
6,951
-896
-11% -$207K 0.03% 607
2023
Q3
$1.77M Buy
7,847
+143
+2% +$32.9K 0.04% 546
2023
Q2
$1.7M Sell
7,704
-116
-1% -$25.7K 0.03% 570
2023
Q1
$1.75M Buy
7,820
+1,468
+23% +$362K 0.04% 555
2022
Q4
$1.77M Buy
6,352
+4,605
+264% +$1.16M 0.04% 541
2022
Q3
$366K Sell
1,747
-228
-12% -$51K 0.01% 1013
2022
Q2
$465K Sell
1,975
-1,212
-38% -$246K 0.01% 961
2022
Q1
$572K Sell
3,187
-22
-0.7% -$4.19K 0.01% 967
2021
Q4
$693K Buy
3,209
+375
+13% +$73.6K 0.01% 917
2021
Q3
$523K Buy
2,834
+362
+15% +$71.3K 0.01% 979
2021
Q2
$444K Buy
2,472
+774
+46% +$147K 0.01% 1045
2021
Q1
$284K Sell
1,698
-43
-2% -$7.17K ﹤0.01% 1141
2020
Q4
$264K Buy
1,741
+128
+8% +$16.8K ﹤0.01% 1139
2020
Q3
$163K Buy
1,613
+747
+86% +$82K ﹤0.01% 1224
2020
Q2
$105K Buy
866
+860
+14,333% +$96.8K ﹤0.01% 1297
2020
Q1
$569 Hold
6
﹤0.01% 1494
2019
Q4
$1K Hold
6
﹤0.01% 1546
2019
Q3
$479 Hold
6
﹤0.01% 1565
2019
Q2
$366 Hold
6
﹤0.01% 1541
2019
Q1
$704 Sell
6
-601
-99% -$70K ﹤0.01% 1558
2018
Q4
$66K Sell
607
-103
-15% -$11.9K ﹤0.01% 1398
2018
Q3
$91K Sell
710
-1,512
-68% -$187K ﹤0.01% 1372
2018
Q2
$252K Sell
2,222
-261
-11% -$28.7K ﹤0.01% 1198
2018
Q1
$288K Sell
2,483
-111
-4% -$14.1K ﹤0.01% 1174
2017
Q4
$384K Sell
2,594
-103
-4% -$13.1K 0.01% 1127
2017
Q3
$316K Sell
2,697
-708
-21% -$90.4K 0.01% 1166
2017
Q2
$442K Sell
3,405
-2,082
-38% -$260K 0.01% 1124
2017
Q1
$743K Buy
5,487
+1,358
+33% +$206K 0.01% 964
2016
Q4
$592K Buy
4,129
+65
+2% +$8.3K 0.01% 1057
2016
Q3
$480K Sell
4,064
-218
-5% -$26.2K 0.01% 1103
2016
Q2
$454K Sell
4,282
-5,883
-58% -$656K 0.01% 1137
2016
Q1
$1.13M Sell
10,165
-8,661
-46% -$1.1M 0.02% 823
2015
Q4
$2.95M Buy
18,826
+31
+0.2% +$4.51K 0.05% 534
2015
Q3
$2.47M Sell
18,795
-7,603
-29% -$1.22M 0.04% 557
2015
Q2
$4.59M Sell
26,398
-1,484
-5% -$267K 0.06% 408
2015
Q1
$4.81M Sell
27,882
-4,566
-14% -$696K 0.06% 384
2014
Q4
$4.2M Sell
32,448
-1,892
-6% -$244K 0.06% 407
2014
Q3
$4.42M Buy
34,340
+2,519
+8% +$260K 0.06% 368
2014
Q2
$2.82M Buy
31,821
+5,394
+20% +$519K 0.04% 490
2014
Q1
$2.48M Buy
26,427
+9,476
+56% +$969K 0.04% 496
2013
Q4
$1.92M Buy
16,951
+3,850
+29% +$347K 0.03% 518
2013
Q3
$1.03M Buy
13,101
+5,153
+65% +$377K 0.02% 664
2013
Q2
$523K Buy
+7,948
New +$512K 0.01% 843

Other funds holding UTHR

Advisors Asset Management's UTHR Position: Q2 2026 in Review

Advisors Asset Management increased its United Therapeutics (UTHR) stake by 38% in Q2 2026, buying an estimated $1.88M and bringing the position to 12,119 shares worth $6.57M. The position accounts for 0.1% of the portfolio, ranked #275.

Advisors Asset Management first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Advisors Asset Management held 12,119 shares of United Therapeutics worth $6.57M as of Q2 2026.
  • Advisors Asset Management bought 3,337 United Therapeutics shares in Q2 2026, an estimated $1.88M.
  • United Therapeutics made up 0.1% of Advisors Asset Management's portfolio in Q2 2026, its #275 holding.
  • Advisors Asset Management first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.